Sage Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Sage Therapeutics Navigates Strategic Review Amidst Pipeline Shift, Reports Full Year 2024 Results
Sage Therapeutics reports its full year 2024 results, highlighting commercialization efforts for ZURZUVAE, pipeline prioritization, and the initiation of a strategic review following an unsolicited acquisition proposal from Biogen.
10-K: Sage Therapeutics 10-K Filing: Focus on Postpartum Depression Treatment and Pipeline Development
Sage Therapeutics' 10-K filing highlights the commercial launch of ZURZUVAE for postpartum depression, ongoing clinical trials, and strategic collaborations.